A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats

作者：McEachern Jennifer A; Bingham John; Crameri Gary; Green Diane J; Hancock Tim J; Middleton Deborah; Feng Yan Ru; Broder Christopher C; Wang Lin Fa; Bossart Katharine N^*

来源：Vaccine, 2008, 26(31): 3842-3852.

DOI：10.1016/j.vaccine.2008.05.016

• henipavirus
• subunit vaccine
• CpG
• mucosal immunity

Nipah virus (NiV) and Hendra virus (HeV) are closely related deadly zoonotic paramyxoviruses that have emerged and re-emerged over the last 10 years. In this study, a subunit vaccine formulation containing only recombinant, soluble, attachment glycoprotein from HeV (sG(HeV)) and CpG adjuvant was evaluated as a potential NiV vaccine in the cat model. Different amounts of sG(HeV) were employed and sG-induced immunity was examined. Vaccinated animals demonstrated varying levels of NiV-specific Ig systemically and importantly, all vaccinated cats possessed antigen-specific IgA on the mucosa. Upon oronasal challenge with NiV (50,000 TCID50), all vaccinated animals were protected from disease although virus was detected on day 21 post-challenge in one animal. The ability to elicit protective systemic and mucosal immunity in this animal model provides significant progress towards the development of a human subunit vaccine against henipaviruses.

• 出版日期2008-7-23
• 单位CSIRO